Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Merkel Cell Carcinoma

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Merkel Cell Carcinoma

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Derived from NCI topic(s): Merkel Cell Carcinoma. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
      source wording
      Source null
      9 more-specific settings
      Bavencio: metastatic Merkel cell carcinoma →Keytruda: metastatic Merkel cell carcinoma →Zynyz: metastatic Merkel cell carcinoma →KEYTRUDA QLEX: metastatic Merkel cell carcinoma →BAVENCIO: metastatic Merkel cell carcinoma with PD-L1 stated without a specific alteration →Stage I Merkel Cell Carcinoma →Stage III Merkel Cell Carcinoma →Stage IV Merkel Cell Carcinoma →recurrent Merkel Cell Carcinoma →

      Study evidence for this setting

      6 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT02155647 · Source cited / selected · Scope: narrower

      Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT02267603 · Source cited / selected · Scope: narrower

      Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT02643303 · Registry condition search · Scope: narrower

      A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

      6 outcome links · 9 safety-group records · 0 quality-of-life measures

      →

      NCT03599713 · Source cited / selected · Scope: narrower

      A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

      6 outcome links · 3 safety-group records · 0 quality-of-life measures

      →

      NCT03783078 · Source cited / selected · Scope: narrower

      Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT04234113 · Registry condition search · Scope: narrower

      Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

      6 outcome links · 17 safety-group records · 0 quality-of-life measures

      →

      Indication-specific source history

      Dated source events, not confirmation of current approval for every use of a drug.

      2017-03-23 · Bavencio (avelumab) · accelerated approval
      release id
      clinical-indications-draft-1
      disease state id
      ds-merkel-cell-carcinoma
      event id
      fda-1c3fad1cf06f7da0
      event date
      2017-03-23
      event kind
      accelerated-approval
      drug or regimen
      Bavencio (avelumab)
      source indication text
      Treatment of adults and pediatrics patients 12 years and older with metastatic merkel cell carcinoma (MCC)
      match phrase
      merkel cell carcinoma
      match status
      candidate
      status category
      verified_clinical_benefit
      has date discrepancy
      0
      source collection
      fda-status-row
      source key
      fda-aa-df15228bd5b4a83c6e37
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      2018-12-19 · Keytruda (pembrolizumab) · accelerated approval
      release id
      clinical-indications-draft-1
      disease state id
      ds-merkel-cell-carcinoma
      event id
      fda-90e7f6194d6a4d07
      event date
      2018-12-19
      event kind
      accelerated-approval
      drug or regimen
      Keytruda (pembrolizumab)
      source indication text
      Treatment of adults and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)
      match phrase
      merkel cell carcinoma
      match status
      candidate
      status category
      verified_clinical_benefit
      has date discrepancy
      0
      source collection
      fda-status-row
      source key
      fda-aa-7a0d3513d8c62371861c
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      2023-03-22 · Zynyz (retifanlimab-dlwr) · accelerated approval
      release id
      clinical-indications-draft-1
      disease state id
      ds-merkel-cell-carcinoma
      event id
      fda-6a81501d39d2e612
      event date
      2023-03-22
      event kind
      accelerated-approval
      drug or regimen
      Zynyz (retifanlimab-dlwr)
      source indication text
      Adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)
      match phrase
      merkel cell carcinoma
      match status
      candidate
      status category
      verified_clinical_benefit
      has date discrepancy
      0
      source collection
      fda-status-row
      source key
      fda-aa-d4ad691142ed2bc68c9b
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      2023-09-06 · Bavencio (avelumab) · traditional approval
      release id
      clinical-indications-draft-1
      disease state id
      ds-merkel-cell-carcinoma
      event id
      fda-32a292af82d3c7ad
      event date
      2023-09-06
      event kind
      traditional-approval
      drug or regimen
      Bavencio (avelumab)
      source indication text
      Treatment of adults and pediatrics patients 12 years and older with metastatic merkel cell carcinoma (MCC)
      match phrase
      merkel cell carcinoma
      match status
      candidate
      status category
      verified_clinical_benefit
      has date discrepancy
      0
      source collection
      fda-status-row
      source key
      fda-aa-df15228bd5b4a83c6e37
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      2023-10-12 · Keytruda (pembrolizumab) · traditional approval
      release id
      clinical-indications-draft-1
      disease state id
      ds-merkel-cell-carcinoma
      event id
      fda-59dfed6da8572e6f
      event date
      2023-10-12
      event kind
      traditional-approval
      drug or regimen
      Keytruda (pembrolizumab)
      source indication text
      Treatment of adults and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)
      match phrase
      merkel cell carcinoma
      match status
      candidate
      status category
      verified_clinical_benefit
      has date discrepancy
      0
      source collection
      fda-status-row
      source key
      fda-aa-7a0d3513d8c62371861c
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      2025-12-17 · Zynyz (retifanlimab-dlwr) · traditional approval
      release id
      clinical-indications-draft-1
      disease state id
      ds-merkel-cell-carcinoma
      event id
      fda-2d50a9c5bf87eb20
      event date
      2025-12-17
      event kind
      traditional-approval
      drug or regimen
      Zynyz (retifanlimab-dlwr)
      source indication text
      Adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)
      match phrase
      merkel cell carcinoma
      match status
      candidate
      status category
      verified_clinical_benefit
      has date discrepancy
      0
      source collection
      fda-status-row
      source key
      fda-aa-d4ad691142ed2bc68c9b
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-merkel-cell-carcinoma
        binding id
        ncit-C9231
        source collection
        ncit-concept
        source key
        C9231
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice